Genitourinary Cancers

Rohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.

Rohit Kumar, MD, discusses the current and future uses of triplet combinations in metastatic renal cell carcinoma.

Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.

The oncologists close their discussion with a look at some currently ongoing clinical trials in advanced renal cell carcinoma treatment.

Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.

Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.

Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.

Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.

Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.

Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Investigators may have discovered a key detail about renal medullary carcinoma that could have significant ramifications for patients.

Michael R. Harrison, MD, discusses the key long-term data of select doublet combinations in renal cell carcinoma, the early investigation of triplet therapy in the frontline setting, and more.

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-125 levels and increased tumor burden and treatment response in this disease.

Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.

The FDA has granted a fast track designation to batiraxcept for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology–based and VEGF TKI–based therapies, either in combination or sequentially.

Mohamad Allaf, MD, discusses innovative and unique aspects of the PROSPER-RCC trial design, areas for continued analysis within the study, and the ways in which this trial will inspire and inform continued research in renal cell carcinoma.

The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.

Daniel J. George, MD, discusses the impact that ADCs have had on the evolving treatment landscape of bladder cancer, long-term outcomes with immunotherapy in metastatic renal cell carcinoma, and highlighted current and ongoing research at the Duke Cancer Institute.

Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.